18 Jan 22. Featured Paper

Association of lipoprotein(a) with atherosclerotic plaque progression

Link to paper on Journal of the American College of Cardiology

Authors

Yannick Kaiser, Marwa Daghem, Evangelos Tzolos, Mohammed N. Meah, Mhairi K. Doris, Alistair J. Moss, Jacek Kwiecinski, Jeffrey Kroon, Nick S. Nurmohamed, Pim van der Harst, Philip D. Adamson, Michelle C. Williams, Damini Dey, David E. Newby, Erik S.G. Stroes, Kang H. Zheng, and Marc R. Dweck

Abstract

Background: Lipoprotein(a) [Lp(a)] is associated with increased risk of myocardial infarction, although the mechanism for this observation remains uncertain.

Objectives: This study aims to investigate whether Lp(a) is associated with adverse plaque progression.

Methods: Lp(a) was measured in patients with advanced stable coronary artery disease undergoing coronary computed tomography angiography at baseline and 12 months to assess progression of total, calcific, noncalcific, and low-attenuation plaque (necrotic core) in particular.

High Lp(a) was defined as Lp(a) ≥ 70 mg/dL.

The relationship of Lp(a) with plaque progression was assessed using linear regression analysis, adjusting for body mass index, segment involvement score, and ASSIGN score (a Scottish cardiovascular risk score comprised of age, sex, smoking, blood pressure, total and high-density lipoprotein [HDL]–cholesterol, diabetes, rheumatoid arthritis, and deprivation index).

Results: A total of 191 patients (65.9 ± 8.3 years of age; 152 [80%] male) were included in the analysis, with median Lp(a) values of 100 (range: 82 to 115) mg/dL and 10 (range: 5 to 24) mg/dL in the high and low Lp(a) groups, respectively.

At baseline, there was no difference in coronary artery disease severity or plaque burden.

Patients with high Lp(a) showed accelerated progression of low-attenuation plaque compared with low Lp(a) patients (26.2 ± 88.4 mm3 vs −0.7 ± 50.1 mm3; P = 0.020).

Multivariable linear regression analysis confirmed the relation between Lp(a) and low-attenuation plaque volume progression (β = 10.5% increase for each 50 mg/dL Lp(a), 95% CI: 0.7%-20.3%).

There was no difference in total, calcific, and noncalcific plaque volume progression.

Conclusions: Among patients with advanced stable coronary artery disease, Lp(a) is associated with accelerated progression of coronary low-attenuation plaque (necrotic core).

This may explain the association between Lp(a) and the high residual risk of myocardial infarction, providing support for Lp(a) as a treatment target in atherosclerosis.

Keywords

• Coronary computed tomography angiography
• Lipoprotein(a)
• Low-attenuation plaque